Kidney Failure ChronicNCT07612124
Evaluation of the Application of Intelligent Applications in Patients Undergoing Peritoneal Dialysis
A study testing Conventional Follow-up and Weiyin Health Smart Application in people with Kidney Failure Chronic and ESRD (End-Stage Renal Disease), run by The Third Xiangya Hospital of Central South University at 1 site in China.
Trial summary
The goal of this clinical trial is to evaluate the value of a smart application named "Weiyin Health" in the follow-up management of patients undergoing peritoneal dialysis. The main questions it aims to answer are: Can the use of a smart application reduce the unplanned readmission rate? Can the use of a smart… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Kidney Failure Chronic, ESRD (End-Stage Renal Disease)
- What is being tested?
- Conventional Follow-up and Weiyin Health Smart Application
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 223 participants
- Where
- 1 siteChina
- Study dates
- 1 Jul 2024to 1 Apr 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 1.Age ≥ 18 years 2.Willing and able to provide signed informed consent 3.Receiving maintenance peritoneal dialysis 4.Has basic reading and comprehension skills and is able to use Internet-based tools such as WeChat
Who cannot join
- 1. History of peritonitis within the past 12 weeks, or active infection requiring systemic antibiotic therapy 2.Hospitalization within 4 weeks prior to screening 3.Severe heart failure (NYHA Class 4), severe malnutrition, malignancy, or any other condition that the investigator judges may affect the evaluation of outcomes 4.Currently participating in another clinical study 5.Psychiatric disorder or cognitive impairment
Trial locations and contacts
1 site in 1 country.
China1 site
Third Xiangya Hospital of Central South University
Changsha, Hunan, 410013
About this study
The goal of this clinical trial is to evaluate the value of a smart application named "Weiyin Health" in the follow-up management of patients undergoing peritoneal dialysis. The main questions it aims to answer are:
Can the use of a smart application reduce the unplanned readmission rate?
Read more
Can the use of a smart application reduce the incidence of peritonitis?
Researchers will compare patients who use the smart application for follow-up with those who receive conventional follow-up.
Eligible patients on peritoneal dialysis will be randomly assigned to one of two groups: one group will receive conventional follow-up (WeChat group + telephone reminders), and the other group will use the "Weiyin Health" smart application for follow-up (including data collection, AI-based Q\&A, follow-up reminders, and risk alerts). Both groups will attend peritoneal dialysis specialty clinic visits once every 3 months for routine check-ups over a 12-month period.
Read the detailed description
Study Design:
This is a prospective, randomized, controlled, open-label study. Eligible patients on peritoneal dialysis will be randomized in a 1:1 ratio to either the conventional follow-up group or the smart application follow-up group. A total of 800 participants are planned for enrollment.
Eligibility Criteria:
Inclusion Criteria:
- Age ≥ 18 years
- Willing and able to provide signed informed consent
- Receiving maintenance peritoneal dialysis
- Has basic reading and comprehension skills and is able to use Internet-based tools such as WeChat
Exclusion Criteria:
- History of peritonitis within the past 12 weeks, or active infection requiring systemic antibiotic therapy
- Hospitalization within 4 weeks prior to screening
- Severe heart failure (NYHA Class 4), severe malnutrition, malignancy, or any other condition that the investigator judges may affect the evaluation of outcomes
- Currently participating in another clinical study
- Psychiatric disorder or cognitive impairment
Interventions:
Conventional Follow-up Group:
- Healthcare providers will organize a WeChat group for patients on peritoneal dialysis, regularly post peritoneal health knowledge in the group, and answer patients' questions in the group
- Traditional telephone calls will be used for follow-up reminders
Smart Application Follow-up Group:
- Patients will download and install the "Weiyin Health" application
- The application provides the following functions:
Data collection AI-based one-on-one Q\&A Follow-up reminders Risk alerts
Common Interventions (Both Groups):
All patients in both groups will attend routine peritoneal dialysis specialty clinic follow-up visits once every 3 months for 12 consecutive months. Follow-up include:
- General assessment and physical examination
- Examination of the PD catheter exit site
- Collection of blood, urine, and peritoneal fluid samples
- Replacement of the external tubing every 6 months
- Personalized health education
Outcome Measures:
Primary Outcome Measures:
- Unplanned readmission rate
- Incidence of peritonitis
- Being tested
- Conventional Follow-up, Weiyin Health Smart Application
- Keywords
- Smart application, Telemedicine, Peritoneal dialysis
- Medical subject headings
- Renal Insufficiency, Chronic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Conventional Follow-upOther
Participants receive conventional follow-up care including a WeChat group for peritoneal dialysis health education and Q\&A, and telephone reminders for follow-up visits.
Weiyin Health Smart ApplicationDevice
Also called Weiyin Health APP
A smart application installed on participants' mobile devices that provides functions including data collection, AI-based one-on-one Q\&A, follow-up reminders, and risk alerts for peritoneal dialysis patients.
| Study group | Role | What they receive |
|---|---|---|
| Conventional Follow-up Group | Active comparator | Participants in this group receive conventional follow-up care. Healthcare providers organize a WeChat group to regularly post peritoneal dialysis health knowledge and answer patients' questions. Traditional telephone calls are used for follow-up reminders. In addition, participants attend routine peritoneal dialysis specialty clinic follow-up visits once every 3 months for 12 months, including physical examination, PD catheter exit site examination, collection of blood/urine/peritoneal fluid samples, external tubing replacement every 6 months, and personalized health education. Receives: Other: Conventional Follow-up |
| Smart Application Follow-up Group | Experimental | Participants in this group receive follow-up care via a smart application named "Weiyin Health". The application provides functions including data collection, AI-based one-on-one Q\&A, follow-up reminders, and risk alerts. In addition, participants attend routine peritoneal dialysis specialty clinic follow-up visits once every 3 months for 12 months, including physical examination, PD catheter exit site examination, collection of blood/urine/peritoneal fluid samples, external tubing replacement every 6 months, and personalized health education. Receives: Device: Weiyin Health Smart Application |
What is being measured
The primary outcome is the main question the study is designed to answer.
Unplanned Readmission Rate
The proportion of participants who experience unplanned hospital readmission during the 12-month follow-up period.
Measured: 12 months
Peritonitis Incidence
The proportion of participants who develop peritonitis during the 12-month follow-up period. Peritonitis is defined according to the International Society for Peritoneal Dialysis (ISPD) criteria.
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 May 2026
- Study start1 Jul 2024
- Primary completion31 Dec 2025
- Study completion1 Apr 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Kidney Failure ChronicStudies of the same condition, open and under way.
- More trials run by The Third Xiangya Hospital of Central South UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants are randomly assigned in a 1:1 ratio to one of two parallel groups: the conventional follow-up group or the smart application follow-up group.
- Masking
- None (open label)
- Enrolment
- 223 participants (actual)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Guoping Yang, The Third Xiangya Hospital of Central South University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07612124
- Sponsor's protocol ID
- 2024167
- Status last verified
- May 2026
- First submitted
- 21 May 2026
- Last updated
- 28 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Application of Intelligent Applications in Patients Undergoing Peritoneal Dialysis
- ClinicalTrials.gov ID
- NCT07612124
- Acronym / sponsor ID
- 2024167
- Keywords
- Smart application, Telemedicine, Peritoneal dialysis
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 223 participants (actual)
- Lead sponsor
- The Third Xiangya Hospital of Central South UniversityUniversity, hospital or other
- Study start
- 1 Jul 2024 (actual)
- Primary completion
- 31 Dec 2025 (actual)
- Study completion
- 1 Apr 2026 (actual)
- First posted
- 28 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to evaluate the value of a smart application named "Weiyin Health" in the follow-up management of patients undergoing peritoneal dialysis. The main questions it aims to answer are:
Can the use of a smart application reduce the unplanned readmission rate?
Can the use of a smart application reduce the incidence of peritonitis?
Researchers will compare patients who use the smart application for follow-up with those who receive conventional follow-up.
Eligible patients on peritoneal dialysis will be randomly assigned to one of two groups: one group will receive conventional follow-up (WeChat group + telephone reminders), and the other group will use the "Weiyin Health" smart application for follow-up (including data collection, AI-based Q\&A, follow-up reminders, and risk alerts). Both groups will attend peritoneal dialysis specialty clinic visits once every 3 months for routine check-ups over a 12-month period.
Detailed description
Study Design:
This is a prospective, randomized, controlled, open-label study. Eligible patients on peritoneal dialysis will be randomized in a 1:1 ratio to either the conventional follow-up group or the smart application follow-up group. A total of 800 participants are planned for enrollment.
Eligibility Criteria:
Inclusion Criteria:
- Age ≥ 18 years
- Willing and able to provide signed informed consent
- Receiving maintenance peritoneal dialysis
- Has basic reading and comprehension skills and is able to use Internet-based tools such as WeChat
Exclusion Criteria:
- History of peritonitis within the past 12 weeks, or active infection requiring systemic antibiotic therapy
- Hospitalization within 4 weeks prior to screening
- Severe heart failure (NYHA Class 4), severe malnutrition, malignancy, or any other condition that the investigator judges may affect the evaluation of outcomes
- Currently participating in another clinical study
- Psychiatric disorder or cognitive impairment
Interventions:
Conventional Follow-up Group:
- Healthcare providers will organize a WeChat group for patients on peritoneal dialysis, regularly post peritoneal health knowledge in the group, and answer patients' questions in the group
- Traditional telephone calls will be used for follow-up reminders
Smart Application Follow-up Group:
- Patients will download and install the "Weiyin Health" application
- The application provides the following functions:
Data collection AI-based one-on-one Q\&A Follow-up reminders Risk alerts
Common Interventions (Both Groups):
All patients in both groups will attend routine peritoneal dialysis specialty clinic follow-up visits once every 3 months for 12 consecutive months. Follow-up include:
- General assessment and physical examination
- Examination of the PD catheter exit site
- Collection of blood, urine, and peritoneal fluid samples
- Replacement of the external tubing every 6 months
- Personalized health education
Outcome Measures:
Primary Outcome Measures:
- Unplanned readmission rate
- Incidence of peritonitis
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Participants are randomly assigned in a 1:1 ratio to one of two parallel groups: the conventional follow-up group or the smart application follow-up group.
| Arm | Type | Receives |
|---|---|---|
| Conventional Follow-up Group | Active comparator | Other: Conventional Follow-upParticipants in this group receive conventional follow-up care. Healthcare providers organize a WeChat group to regularly post peritoneal dialysis health knowledge and answer patients' questions. Traditional telephone calls are used for follow-up reminders. In addition, participants attend routine peritoneal dialysis specialty clinic follow-up visits once every 3 months for 12 months, including physical examination, PD catheter exit site examination, collection of blood/urine/peritoneal fluid samples, external tubing replacement every 6 months, and personalized health education. |
| Smart Application Follow-up Group | Experimental | Device: Weiyin Health Smart ApplicationParticipants in this group receive follow-up care via a smart application named "Weiyin Health". The application provides functions including data collection, AI-based one-on-one Q\&A, follow-up reminders, and risk alerts. In addition, participants attend routine peritoneal dialysis specialty clinic follow-up visits once every 3 months for 12 months, including physical examination, PD catheter exit site examination, collection of blood/urine/peritoneal fluid samples, external tubing replacement every 6 months, and personalized health education. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- 1.Age ≥ 18 years 2.Willing and able to provide signed informed consent 3.Receiving maintenance peritoneal dialysis 4.Has basic reading and comprehension skills and is able to use Internet-based tools such as WeChat
Key exclusion criteria (1 listed)
- 1. History of peritonitis within the past 12 weeks, or active infection requiring systemic antibiotic therapy 2.Hospitalization within 4 weeks prior to screening 3.Severe heart failure (NYHA Class 4), severe malnutrition, malignancy, or any other condition that the investigator judges may affect the evaluation of outcomes 4.Currently participating in another clinical study 5.Psychiatric disorder or cognitive impairment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Conventional Follow-upParticipants receive conventional follow-up care including a WeChat group for peritoneal dialysis health education and Q\&A, and telephone reminders for follow-up visits. | Other | Conventional Follow-up Group |
| Weiyin Health Smart ApplicationAlso: Weiyin Health APPA smart application installed on participants' mobile devices that provides functions including data collection, AI-based one-on-one Q\&A, follow-up reminders, and risk alerts for peritoneal dialysis patients. | Device | Smart Application Follow-up Group |
Primary outcome
Unplanned Readmission Rate
Time frame: 12 months
The proportion of participants who experience unplanned hospital readmission during the 12-month follow-up period.
Peritonitis Incidence
Time frame: 12 months
The proportion of participants who develop peritonitis during the 12-month follow-up period. Peritonitis is defined according to the International Society for Peritoneal Dialysis (ISPD) criteria.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 May 2026.
- Individual participant dataSharing planned: No
Related trials for Kidney Failure Chronic
Active, not recruitingPhase 2
Safety and Efficacy of Empagliflozin in Hemodialysis
End Stage Renal Disease
RecruitingPhase 3
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
Berger Disease, Bergers Disease
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruiting
Hypothermic Kidney Machine Perfusion With Omnisol
End Stage Renal Disease (ESRD), Kidney Transplant
Not yet recruiting
An Individuation Intervention to Reduce Socioeconomic Disparities in Chronic Kidney Disease Care
Chronic Kidney Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Conventional Follow-up and Weiyin Health Smart Application in people with Kidney Failure Chronic and ESRD (End-Stage Renal Disease), run by The Third Xiangya Hospital of Central South University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Unplanned Readmission Rate (time frame: 12 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 May 2026.